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Structure of the 70-kDa Soluble Lytic Transglycosylase Complexed with 
Bulgecin A. Implications for the Enzymatic Mechanism? 
Andy-Mark W. H. Thunnissen,t Henriette J. Rozeboom, Kor H. Kalk, and Bauke W. Dijkstra* 
Laboratory of Biophysical Chemistry and BIOSON Research Institute, Department of Chemistry, University of Groningen, 
Nijenborgh 4, 9747 AG Groningen, The Netherlands 
Received June 5, 1995; Revised Manuscript Received August 1, 1995@ 
ABSTRACT: Bulgecins are 0-sulfonated glycopeptides that are able to enhance the antibacterial activity of 
p-lactam antibiotics. The 70-kDa soluble lytic transglycosylase (SLT7O) from Escherichia coli forms a 
specific target of these compounds. Using X-ray crystallograph the three-dimensional structure of a 
of 19.5%. The model contains all 618 amino acids of SLT70 and a single molecule of bound bulgecin, 
located in the active site of the enzyme. The glycopeptide inhibitor is bound in an extended conformation 
occupying sites analogous to the B, C, and D subsites of lysozyme. Upon binding of bulgecin, the three- 
stranded antiparallel /3-sheet in the C domain shows a pronounced shift toward the inhibitor. In subsite 
D, the proposed catalytic residue Glu478 forms a hydrogen bond to the hydroxymethyl oxygen of the 
proline part of bulgecin and interacts electrostatically with the proline NH2+ group. These interactions, 
in addition to the interactions observed for the 2-acetamido group of the N-acetylglucosamine residue 
bound in subsite C, may explain the strong inhibition of SLT70 activity by bulgecin, suggesting that 
bulgecin acts as an analogue of an oxocarbonium ion intermediate in the reaction catalyzed by SLT70. 
The structure of the SLT70-bulgecin A complex may be of assistance in the rational design of novel 
antibiotics. 
complex of SLT70 with bulgecin A has been determined to 2.8- t resolution and refined to an R factor 
The lytic transglycosylases from Escherichia coli are a 
group of bacterial exomuramidases involved in the metabo- 
lism of the cell wall peptidoglycan. These enzymes catalyze 
the cleavage of the P-1,4-glycosidic bond between N- 
acetylmuramic acid (MurNAc)l and N-acetylglucosamine 
(GlcNAc) residues. Whereas lysozymes accomplish the 
cleavage by hydrolyzing the glycosidic bonds, the lytic 
transglycosylases carry out an intramolecular glycosyl trans- 
ferase reaction resulting in the formation of 1,6-anhydro- 
muropeptides (Holtje et al., 1975). Different functions for 
the lytic transglycosylases have been suggested (Holtje & 
Tuomanen, 1991), including a role as space maker for the 
insertion of new peptidoglycan material during growth and 
remodeling of the cell wall, a role as cell wall zipper during 
cell division, and a function in the recycling of old pepti- 
doglycan material. Since the activity of these enzymes is 
potentially suicidal for the organism (Kitano et al., 1986), it 
must be under strict control, and it must be precisely 
coordinated with the action of peptidoglycan-synthesizing 
enzymes for orderly growth and division of the cell without 
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disrupting the integrity of the cell wall. The mechanisms 
by which the bacterium accomplishes these highly sophis- 
ticated tasks are still far from understood. 
Three different lytic transglycosylases have been isolated 
from E. coli, two are soluble proteins located in the 
periplasmic space with molecular masses of 70 and 35 kDa 
(Holtje et al., 1975; Engel et al., 1992), the other is a 
membrane-bound protein of 38 kDa (Romeis et al., 1993; 
Ursinus & Holtje, 1994). The 70-kDa soluble lytic trans- 
glycosylase (SLT70) has been studied in most detail, both 
biochemically (Beachey et al., 1981; Keck et al., 1985; 
Kusser & Schwarz, 1980) and genetically (Betzner & Keck, 
1989; Engel et al., 1991). Recently, the three-dimensional 
structure has been obtained by X-ray crystallography (Thun- 
nissen et al., 1994). The crystal structure of SLT70 is 
composed of three domains, two of which form a novel 
“superhelical” ring of a-helices, while the third C-terminal 
domain has a lysozyme-like fold. The active site of SLT70 
is located in the C-terminal domain. While Glu478 has been 
proposed to have a similar role as the “catalytic” glutamic 
acid in lysozymes, SLT70 lacks the catalytic aspartate residue 
that is commonly found in the active site of lysozymes. From 
a comparison with the three distinct types of lysozyme 
(chicken, phage, goose-type) with known three-dimensional 
structure, it could be shown that the C-domain of SLT70 
defines a novel bacterial-type lysozyme (Dijkstra & Thun- 
nissen, 1995; Thunnissen et al., 1995) that is characterized 
by the occurrence of a limited number of differences in the 
arrangement of secondary structure elements and by the 
absence of an aspartate in the catalytic site. The closest 
relationship was found with the structure of a member of 
the goose-type lysozymes. Interestingly, as was shown 
recently (Weaver, 1995), the goose-type lysozymes also lack 
a catalytic aspartate residue. 
0 1995 American Chemical Society 
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FIGURE 1: Structure of bulgecins. Bulgecins consist of a 4-0- 
sulfonyl-N-acetylglucosamine residue that is linked with a 
semi-p- 1,4-glycosidic linkage to a 4-hydroxy-5-(hydroxymethyl)- 
L-proline. Bulgecins are produced by P. acidophila and P. 
mesoacidophila in three different forms, A-C, which differ in the 
moiety that is linked to the carboxylic group of the proline. Bulgecin 
A constitutes the major component. It contains a taurine residue, 
which is linked to the proline via an amide bond. In bulgecin B 
the proline is linked to a p-alanine, whereas in bulgecin C the 
proline has a free carboxylic group. 
Little is known about the catalytic mechanism of SLT70. 
Also the functional importance of SLT70 is still unclear. The 
enzyme is no target for p-lactam antibiotics. E. coli mutants 
that lack the SLT70 gene do not show a specific phenotype 
and grow normally under standard conditions (Templin et 
al., 1992). This result, however, may be explained by the 
redundancy that exists in the set of peptidoglycan-degrading 
enzymes in E. coli (Holtje & Tuomanen, 1991), and the 
function of SLT70 may be taken over by the other lytic 
transglycosylases. Interestingly, the SLT70-deficient mutants 
are much more sensitive toward p-lactam antibiotics than 
normal cells and form bulges prior to rapid bacteriolysis 
when exposed to p-lactams. Similar morphological alter- 
ations occur in wild-type E. coli cells when the p-lactams 
are combined with compounds known as bulgecins. These 
are a group of 0-sulfonated glycopeptides produced by 
Pseudomonas acidophila and Pseudomonas mesoacidophila 
(Shinagawa et al., 1985) (Figure 1). Although by themselves 
bulgecins are devoid of any antibacterial activity, in com- 
bination with p-lactam antibiotics they induce bulge forma- 
tion in the cell wall of Gram-negative bacteria and potentiate 
the lytic activity of the p-lactam antibiotics. It has been 
shown that one of the bulgecins (bulgecin A) specifically 
inhibits SLT70 (Templin et al., 1992), thus explaining the 
similar susceptibility toward antibiotics of SLT70-deficient 
E. coli strains and of E. coli bacteria grown in the presence 
of bulgecin. 
To understand the structural basis for the mode of 
inhibition by bulgecin, and to increase our understanding of 
the catalytic function of the lytic transglycosylases, we have 
determined the structure of the SLT70-bulgecin A complex 
by X-ray crystallography at 2.8-A resolution. The results 
clearly show that bulgecin A is bound in the active site of 
SLT70 interacting with the catalytic Glu478. The structure 
of the complex suggests that bulgecin mimics the oxocar- 
bonium ion intermediate. 
MATERIALS AND METHODS 
Preparation and Data Collection of the SLT70- Bulgecin 
Crystals. Crystallization of native SLT70 crystals has been 
Table 1: Statistics of Data Collection and Processing 
data set FAST image plate 
X-ray source,n wavelength (A) ROTA, 1.542 SYN, 1.003 
no. of crystals 2 4 
cell parameters (A) 
a 79.70 80.3 1 
b 88.24 88.47 
C 132.4 133.1 
resolution range (A) 25-3.10 22-2.80 
no. of unique data 15997 23903 
data redundancy 1.9 4.8 
completeness (%) 90 99 
Rmergeb 8.7 8.0 
Rlso‘ 20.4 23.4 
a ROTA, rotating anode; SYN, synchrotron. Rmerge = CM,Z.refiJ/ l<MiJ) 
- r,hk,l/Chkrx:,fiJl~hkn. RISO = 21 IFa,bulpecinl - iFo,natwe/ I / x / F o , n a t i d ,  
described previously (Rozeboom et al., 1990). Crystals of 
SLT70 belong to spacegroup P212121 with a = 80.8 A, b = 
88.4 A, and c = 132.6 A and contain one molecule per 
asymmetric unit. Crystals of the SLT70-bulgecin complex 
were obtained by soaking native crystals for 48 h at room 
temperature in a solution of 40% saturated (NH4)2S04 in 0.1 
mM NaOAc, pH 5.0, containing 7 mM bulgecin A. Initially, 
data from 25 to 3.1 A were collected on an Enraf-Nonius 
FAST area detector mounted on a Elliot GX-21 rotating 
anode X-ray generator operating at 40 kV and 75 mA. Data 
processing was cmied out with the MADNES software 
system (Messerschmidt & Pflugrath, 1987), complemented 
with Kabsch profile fitting (Kabsch, 1988). Merging of the 
data into a unique set of structure factor amplitudes was 
performed with programs of the BIOMOL (Groningen, The 
Netherlands) software package. The structure factor ampli- 
tudes of the SLT70-bulgecin A complex were scaled to the 
native SLT70 data using the program KBRANI (BIOMOL), 
and an Fo,comp~ex - Fo,native difference map at 3.5-A resolution 
was calculated with observed structure factor amplitudes and 
phases calculated from the native structure. This map clearly 
indicated the presence of the bulgecin in the putative active 
site of SLT70. A new data set of the complex was collected 
to 2.8-A resolution on the image plate system at beamline 
X31 of the EMBL Outstation at the DESY synchrotron, 
Hamburg. The image plate data were processed with the 
MOSFLM software (Leslie, A. G. W, MRC, Cambridge, 
UK) and merged with programs from the CCP4 package 
(Collaborative Computational Project Number 4, 1994). The 
synchrotron data set was used in the refinement of the 
SLT70-bulgecin complex. A summary of the data collec- 
tion and processing statistics is given in Table 1. 
Structure Refinement. The structure of the SLT70- 
bulgecin complex was refined starting from the native model 
of SLT70 (Thunnissen et al., 1994). The initial R factor was 
29% with all data from 8 to 2.8 A. First, a three-dimensional 
rigid-body refinement of this model in the 8-3.5-A resolu- 
tion range was carried out using the program X-PLOR 
(Briinger, 1992a). Next, the protein model, still without the 
inhibitor, was subjected to a few rounds of positional 
refinement against data from 8.0 to 2.8 A with lFol > 2 0  
using the “conventional” energy minimization routine in 
X-PLOR. The significance of the refinement was continu- 
ously monitored by cross-validation with the free R factor 
(Briinger, 1992b), which was calculated from 10% of the 
data omitted from the refinement. Small adjustments were 
made to the protein model, and addition of the bulgecin 
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region. The estimated rms coordinate error, derived from a 
OA plot (Read, 1986), is -0.4 A. From the F, - F, 
difference electron map (Figure 2A) it can be seen that, 
except for the taurine part, the inhibitor has well-defined 
electron density. The S4, C 7 , 0 ,  C5, and OH atoms occupy 
peaks in the electron density map of 19, 11, 11, 9, and 8 
times the standard deviation, respectively. The average B 
factor for the bulgecin atoms, excluding those of the taurine 
moiety, is 12.9 A2, while the average B factor for the taurine 
atoms is 41.8 A2. 
Interactions between Bulgecin and the Active Site of 
SLT70. The crystal structure of native SLT70 has been 
previously described (Thunnissen et al., 1994). Bulgecin A 
is bound to SLT70 at a single site per protein molecule 
(Figure 2B), located in the region of the active site cleft that 
is analogous to subsites B, C, and D of the lysozymes 
(Thunnissen et al., 1995). The inhibitor adopts an extended 
conformation with the 4-0-sulfonate group of the GlcNAc 
residue located at subsite B, the GlcNAc bound in subsite 
C, and the proline residue bound in subsite D. The taurine 
part of bulgecin A that is linked to the proline points outward 
from subsite D toward the solvent. Specific interactions 
between bulgecin A and SLT70 occur in both subsites C 
and D (Figure 3; Table 3). The 4-0-sulfonate group of 
GlcNAc in subsite B makes no direct hydrogen bonds with 
any protein atoms and is largely accessible to solvent. It 
may be that binding of this group occurs through water 
molecules, but the resolution of the SLT70-bulgecin com- 
plex does not allow the identification of such interactions. 
The sulfonate group is positioned at -4 A from the 
N-terminus of helix Ca6  [residues 556-559 of SLT70; 
Thunnissen et al. (1994)], coinciding with the helical axis. 
This suggests that it may have an electrostatic interaction 
with the a-helix dipole moment (Hol, 1985). In addition, 
the position of the sulfonate group might be stabilized by 
an intramolecular hydrogen bond interaction with the 0 6  of 
the GlcNAc residue; the distance between this atom and one 
of the sulfonate oxygens is 2.8 A. 
In subsite C, the 2-acetamido group of the GlcNAc residue 
is bound between two backbone segments of SLT70 with 
hydrogen bonds from the N2 atom to the main-chain C-0 
of Tyr552, and from the 0 7  atom to the main-chain NH of 
Met498. In addition, a strong van der Waals contact is made 
by the C8 methyl group and the side chain of Tyr552. 
Adjacent to the 2-acetamido group, the 3-hydroxy 0 3  of 
GlcNAc makes hydrogen bonds with the side chains of 
Tyr533 and Th5O 1, respectively. The 5-hydroxymethyl 
group of GlcNAc is not involved in any hydrogen bond with 
protein atoms. 
In subsite D, the hydroxymethyl oxygen of the proline 
residue of bulgecin makes a direct hydrogen bond with the 
Oc2 atom of the catalytic Glu478. Another hydrogen bond 
occurs between the carbonyl oxygen of the proline and the 
side chain of Ser487. Furthermore, an electrostatic interac- 
tion might occur between the amine of the proline and the 
side chain of Glu478. The amine is located -4 A away 
from the 061 atom of Glu478. Since it has a pK, higher 
than 9 [Hall (1957) and Handbook of Biochemistry (1968)], 
at the pH of this experiment (pH 5) we would expect this 
group to bear two protons and a net positive charge. In the 
SLT70-bulgecin complex, the side chain of Glu478 is most 
probably ionized, thereby stabilizing the NH2+ group of the 
bulgecin. 
Table 2: Refinement Statistics for SLT70-Bulgecin A Complex 
resolution range (A) 
R factors (no. of reflections)a 
R ~ I I  
Rwork 
Riree 
no. of protein atoms 
no. of water molecules 
no. of bulgecin atoms 
RMS deviations from idealityb 
bond distances (A) 
angles (deg) 
dihedrals (deg) 



















' R factor = c ~ i F o ~  - lFc/I/CIFol. R,IIis calculated for all reflections 
in the resolution range. Rwork and Rfree are defined for reflections with 
IF1 > 20. Rfree has been calculated from reflections that were not 
included in the actual refinement. With respect to Engh and Huber 
(1991) parameter set. The values in parentheses are the average 
deviations in B factors between bonded atoms. 
inhibitor was based on F, - F, and 2F, - F, Fourier maps. 
The glycopeptide inhibitor was built from the X-ray coor- 
dinates of a desulfated form of bulgecin A (Shinagawa et 
al., 1984) using the program BIOGRAF version 3.1 (Mo- 
lecular Simulations Inc., Waltham, MA) and adjusted manu- 
ally to fit the difference electron density using the program 
0 (Jones et al., 1991). A topology file was constructed for 
the glycopeptide inhibitor together with a file containing the 
force constants and parameters necessary to restrain the 
geometry of bulgecin A during the refinement. Then, the 
model of the SLT70-bulgecin complex was optimized by 
further rounds of positional and B-factor refinement. Table 
2 contains a summary of the refinement statistics. No water 
molecules were added to the model. 
Structure Analysis. Assessment of the stereochemical 
quality of the protein model was carried out using the 
PROCHECK program (Laskowski et al., 1993). Further 
analysis of the SLT70-bulgecin structure was done with 
programs of the BIOMOL and CCP4 software packages. 
Figures 4, 5a, 6, and 8 were produced with MOLSCRIPT 
(Kraulis, 1991). Coordinates of the SLT70-bulgecin A 
complex have been deposited with the Brookhaven Protein 
Data Bank (entry 1SLY). 
RESULTS 
Accuracy of the SLT70-Bulgecin Model. The refined 
model of the SLT70-bulgecin complex has a crystal- 
lographic R factor of 19.5% for all data between 8 and 2.8 
A with good geometry (Table 2). The R factors for the 
working set and the free set of reflections [Rwork and Rkee; 
Briinger (1992b)l are 18.5% and 26.8%, respectively. 
Electron density for the protein backbone is well defined 
except for residues 37 1-377, which form part of a flexible 
loop at the surface of the protein. The average B factors for 
main-chain and side-chain atoms are 21.4 and 26.9 A2, 
respectively. Analysis of the (q, q)  dihedral angles (Morris 
et al., 1992) shows that 499 (90.2%) of the non-glycine and 
non-proline residues are in the most favored regions, while 
the other 54 residues (9.8%) are in the additional allowed 
regions. No amino acid residues are found in a disallowed 
12732 Biochemistry, Vol. 34, No. 39, 1995 
A 
Thunnissen et al. 
B 
FIGURE 2: (A) Stereoview of final F, - F, difference electron density for bulgecin in the active site of SLT70 at 2.8-A resolution. Only 
the protein atoms of the SLT70-bulgecin complex were included in the F, calculations. The map is contoured at 3 a  of the electron density. 
(B) Stereofigure showing the C a  backbone (thin lines) of SLT70 with bound bulgecin A (thick lines). Every twentieth amino acid residue 
has been numbered. The binding site of bulgecin is located in the C domain of SLT70 (residues 449-618). The U domain (residues 
1-360) and L domain (residues 381-448) make a superhelical ring that forms the basis of the SLT70 doughnut. No binding of bulgecin 
was observed to the latter two domains. 
The taurine part of the inhibitor forms only a few contacts 
with protein atoms, including a hydrogen bond between the 
amide N3 and the side chain of Glu583. Most of the 
sulfonate group of the taurine is accessible to solvent. 
Conformational Changes Associated with the Binding of 
Bulgecin. Upon binding of bulgecin, the antiparallel @-sheet 
of SLT70 moves toward the inhibitor (Figure 4). Compared 
to the uncomplexed SLT70, the p-sheet (residues 483-499) 
shows an overall rms difference in position of 1.0 A for main- 
chain atoms and 1.1 8, for side-chain atoms (for all 618 
residues of SLT70 these numbers are 0.4 and 0.6 A, 
respectively). Movement of the backbone is most pro- 
nounced for the first two p-strands at subsite D, with a 
maximum shift of up to 2 A occurring at Pro489 and Val490 
in the p l  -p2 turn. The movement of the p-sheet optimizes 
the contacts with bulgecin. In particular, the side chain of 
Ser487 moves to a position where it is able to form a 
hydrogen bond with the carbonyl 0 of the proline part of 
bulgecin. Due to the concerted movement of all three 
strands, the hydrogen-bonding network of the /?-sheet is not 
distorted. 
Apart from the movement of the p-sheet, there are no 
dramatic changes in the conformation of residues around the 
bulgecin binding site. The nine side chains, which have at 
least one atom within 4.0 A from bulgecin, excluding those 
in the /3-sheet, show a rms difference in atomic positions of 
only -0.5 A. These displacements are not substantially 
greater than the estimated coordinate error. 
DISCUSSION 
Mode of Inhibition of Bulgecin A. The observed binding 
mode of bulgecin A is hard to associate with a noncompeti- 
tive inhibition of SLT70 activity, as was suggested by a 
previous study (Templin et al., 1992). Our results clearly 
demonstrate that bulgecin is an active site inhibitor. The 
affinity of bulgecin for the active site of SLT70 can be 
explained by the structural similarity of this compound to 
the disaccharide subunit of peptidoglycan. The hydrogen 
bonds and hydrophobic interactions of the acetamido group 
in subsite C are the same as observed in lysozymes 
complexed with inhibitors (Weaver et al., 1985). At subsite 
D, the interactions of Glu478 with the hydroxymethyl group 
and the NH2+ group of the proline part of bulgecin may also 
contribute significantly to the binding, explaining the strong 
inhibition of SLT70 by bulgecin: already 50% of the SLT70 
activity is lost in the presence of 0.42 pM bulgecin (Templin 
et al., 1992). In fact, the hydrogen-bonding distance between 
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FIGURE 3: Protein-inhibitor interactions in the SLT70-bulgecin complex. (A) Stereodiagram showing the refined structure of bulgecin in 
the active site cleft of SLT70. Inferred hydrogen bonds are shown as thin dotted lines. Oxygen atoms are shown filled, nitrogen atoms 
half-filled, and carbon atoms as open circles. (B) Schematic illustration of the inferred interactions between bulgecin and SLT70, including 
the van der Waals contact between the 2-acetamidomethyl group of GlcNAc in subsite C and the side chain of Tyr552. 
Table 3: Summary of Bulgecin-Protein Interactions 
inferred hydrogen bonds" 
subsite bulgecin atom protein atom distance (A) residues in van der Waals contactb 
S-GlcNAc C N2 Tyr552 0 2.9 Ile497 Met498 Thr501 
0 7  Met498 N 2.8 Tyr533 Tyr552 Asn553 
0 3  Thr501 O y l  3.2 Ala554 Gly555 Leu556 
pro 1 in e D OH Glu478 062 2.5 Glu478 Val489 Ala491 
0 Ser487 Oy 2.9 Gln496 Tyr552 Asn553 
taurine N3 Glu583 062 3.3 Pro488 Val489 Glu583 
Tyr533 OH 2.8 
a The maximum length of an allowed hydrogen bond was 3.3 A. Van der Waals contacts are defined for distances less than 4 A, excluding 
possible hydrogen bond interactions. 
the catalytic Glu478 and the hydroxymethyl oxygen of 
bulgecin's proline at subsite D is the shortest of all putative 
hydrogen-bonding interactions of bulgecin, suggesting a 
strong interaction. The presence of the hydroxymethyl group 
at the proline is essential for the inhibition of SLT70 by 
bulgecin, since bulgecin lacking this group does not show 
any synergistic activity with p-lactam antibiotics (Wakamiya 
et al., 1987). 
Bulgecin Mimicking of the Oxocarbonium Ion Reaction 
Intermediate. In the proposed mechanism for hen egg white 
lysozyme (HEWL) (Blake et al., 1967; Phillips, 1967) the 
catalytic glutamic acid (Glu35) acts as a general acid that 
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FIGURE 4: Stereoview showing a three-dimensional superposition of the C a  backbones of the C domain in the SLT70-bulgecin complex 
(thick lines) and uncomplexed, native SLT7O (dashed lines). Bulgecin is also shown. Note the movement of the P-sheet toward the inhibitor. 
donates a proton to the glycosidic oxygen of the scissile bond, 
resulting in bond cleavage and formation of an oxocarbonium 
ion intermediate. Formation of the oxocarbonium ion 
intermediate is favored and stabilized by the steric distortion 
of the MurNAc residue bound in subsite D from a low-energy 
chair conformation toward a higher energy half-chair or sofa 
conformation and by the electrostatic interaction with the 
carboxylate group of the catalytic aspartate (Asp52). Sub- 
sequently, the leaving group at subsite E diffuses away from 
the active site and is replaced by a water molecule. This 
water molecule, presumably activated by Glu35, then attacks 
the C 1 carbon atom of the oxocarbonium ion, thus complet- 
ing the reaction with retention of configuration at C 1. Over 
the past years the proposed mechanism of lysozyme has been 
the subject of several controversies. Especially the stabilizing 
role of the catalytic aspartate and the proposed steps 
involving the ground-state distortion of the D sugar have 
been debated. For the lysozyme from bacteriophage T4 
(T4L), at least two different mechanisms have been proposed 
with the catalytic aspartate acting as a nucleophile to generate 
a covalent glycosyl-enzyme intermediate (Hardy & Poteete, 
1991; Koshland, 1953) or as a base activating a water 
molecule for nucleophilic attack in a single displacement 
reaction (Kuroki et al., 1993). The conformation of the sugar 
in subsite D has been controversial due to lack of experi- 
mental evidence. However, in the last three years, three 
independent high-resolution X-ray diffraction studies of 
different lysozyme-oligosaccharide complexes have been 
reported which clearly show a distorted sugar residue in 
subsite D (Hadfield et al., 1994; Kuroki et al., 1993; 
Strynadka & James, 1991). 
A possible reaction mechanism for SLT70, compared to 
that for HEWL, is shown in Figure 5 .  Since SLT70 lacks 
the catalytic aspartic acid and, moreover, produces nonre- 
ducable 1,6-anhydromuropeptides, at least in some aspects 
the reaction mechanism of SLT7O has to be different from 
that of HEWL. The first step of the reaction, formation of 
an oxocarbonium ion intermediate, may be similar, with 
Glu478 in SLT70 having a role equivalent to Glu35 in 
HEWL. The next reaction steps, however, are likely to be 
different. Instead of a water molecule, the C6-hydroxyl 
group of the MurNAc performs an intramolecular nucleo- 
philic attack on the C1 carbon of the oxocarbonium ion in 
SLT70. Such an attack requires that the glycosidic ring of 
the oxocarbonium ion adopts a boat conformation with the 
C5-hydroxymethyl group in an axial position (Figure 5). Only 
then the C6-hydroxyl group will be able to optimally 
approach the C1 carbon for a nucleophilic attack. The 
catalytic Glu478 may assist in the activation of the C6- 
hydroxyl group by abstracting its proton. As mentioned 
earlier (Thunnissen et al., 1994), the intramolecular nucleo- 
philic attack by the C6-hydroxyl group would probably 
require a shorter lifetime of the oxocarbonium intermediate, 
and thus less stabilization, as it is no longer dependent on 
the diffusion-controlled replacement of the leaving group 
with a water molecule, explaining why there is no need for 
a catalytic aspartate in SLT70. Alternatively, the oxocar- 
bonium ion could be stabilized by a favorable interaction 
with the carbonyl oxygen atom of the N-acetyl group of the 
substrate (see below). 
The structure of the SLT70-bulgecin complex provides 
support for several of the proposed steps of the reaction 
mechanism. Close examination of the bulgecin structure 
reveals that the proline part of the inhibitor mimics the 
oxocarbonium intermediate. The conformation of the proline 
ring with Ca ,  Cd, Cy, and the ring nitrogen almost coplanar 
and the semiaxial position of the hydroxymethyl group trans 
to the Cy-01 substituent is very similar to the sofa 
conformation of the oxocarbonium sugar. Furthermore, the 
charge distribution in the proline with a positive charge on 
the nitrogen is similar to that in the oxocarbonium ion, where 
the positive charge is delocalized between C1 and 05.  
Therefore, the interactions of the proline part of bulgecin in 
subsite D may be relevant for the interactions that play a 
role in the reaction mechanism of SLT70. To explore this 
possibility further, we modeled a GlcNAc-MurNAc disac- 
charide with the sugar ring of MurNAc in a sofa conforma- 
tion on the basis of the observed binding of bulgecin to 
SLT70. Coordinates of the disaccharide were obtained from 
the X-ray structure of the complex of a T4L mutant with a 
cell wall muropeptide from E. coli (Kuroki et al., 1993). The 
result of the model building is shown in Figure 6. If the 
GlcNAc of the disaccharide is fixed to the position of 
GlcNAc of bulgecin in subsite C, the MurNAc sugar in 
subsite D fits remarkably well on the proline of bulgecin, 
without any need to rotate the p- 1,4-glycosidic bond. In the 
superposed structures, the C2, C3, C4, and C5 atoms in the 
MurNAc ring of the disaccharide are very close to the Ca ,  
Cp, Cy, and C6 atoms of the proline ring of bulgecin, while 
the nitrogen of the proline ring is located in between the C1 
and 0 5  atoms of the glucose ring. Moreover, the Shy-  
droxymethyl group of MurNAc occupies a position equiva- 
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FIGURE 5: Proposed steps in the catalytic mechanism of SLT70 compared to the general-acid catalytic pathway of HEWL, as proposed by 
Phillips (1967). Glu478 in SLT70 is the equivalent of Glu35 in HEWL. However, there is no equivalent in SLT70 for Asp52 in HEWL 
(Thunnissen et al., 1994, 1995). The nomenclature of the different conformations of the sugar ring follows the IUPAC rules (Schwarz, 
1973). 
lent to the Cd-hydroxymethyl group of bulgecin and is able 
to make a similar hydrogen bond interaction with Glu478. 
In fact, in the T4L-muropeptide complex, the 5-hydroxym- 
ethyl group of the MurNAc makes such a hydrogen bond 
with the “catalytic” Glu of T4L (Kuroki et al., 1993). If the 
MurNAc in subsite D adopts a normal chair conformation, 
it is impossible to obtain the same spatial overlaps. The only 
unfavorable contact observed is for the 0 7  carbonyl atom 
of the MurNAc 2-acetamido group, which clashes with the 
side chain of Glu583. However, a rotation about the C2- 
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FIGURE 6: Stereodiagram showing a superposition of the GlcNAc-MurNAc cell wall fragment that is covalently linked to the active site 
of a T4L mutant (Kuroki et al., 1993) and bulgecin as found in the SLT70-bulgecin complex. GlcNAc-MurNAc is shown in ball-and- 
stick representation, bulgecin in bonds only. The four-residue peptide, which is linked to the lactyl group of MurNAc, has been omitted. 
The superposition is based on the optimal fit of the GlcNAc residues. No rotations were applied around the glycosidic bond between the 
GlcNAc and MurNAc residue. Only the 2-acetamido group of the MurNAc was reoriented such that it shows optimal correspondence with 
the bulgecin atoms. Possible hydrogen bonds between the disaccharide and active site residues of SLT70 are indicated with dotted lines. 
Atom representations as in Figure 3A. 
N2 bond in MurNAc will not only remove this bad contact 
but may bring the acetamido group in a position allowing it 
to make interactions similar to those observed in the SLT70- 
bulgecin complex. With a C1 -C2-N7-C7 torsion angle 
of --50°, and the C7-08 bond cis to N2-C2, the N2 atom 
of the acetamido group of MurNAc occupies a position close 
to the N3 atom of bulgecin, and it is within hydrogen- 
bonding distance to the 062 of Glu583, while the acetamido 
0 7  atom is spatially close to the carbonyl 0 atom of bulgecin 
and may form a hydrogen bond to Ser487. Interestingly, 
this alternative conformation of the acetamido group allows 
for an intramolecular participation of this substituent in the 
SLT7O-catalyzed glycosyl transferase reaction. The proposed 
interaction of the negatively charged Glu583 with the amide 
of the acetamido group would induce a positive charge on 
the amide nitrogen and a negative charge on the carbonyl 
oxygen. Since the carbonyl oxygen is located under the 
pyranose ring -3 A from the C1 atom, the interaction 
between its negative charge and the (partial) positive charge 
on the C1 atom may provide extra stabilization of the 
oxocarbonium ion (Figure 7). Such an intramolecular 
participation of the 2-acetamido group has been established 
from studies on the nonenzymatic hydrolysis of glycosides 
(Piszkiewicz & Bruice, 1968). It has even been suggested 
as an alternative mechanism for the HEWL-catalyzed reac- 
tion (Lowe, 1967), but so far no evidence for such a model 
has been reported. However, it forms a very interesting 
hypothesis for the mechanism of the SLT7O-catalyzed 
reaction. It would offer an additional explanation why 
SLT70 does not need a catalytic aspartate in the active site. 
The interaction of the acetamido carbonyl 0 7  and the C1 
carbon might also explain why the boat form of the 
oxocarbonium ion intermediate is favored (Figure 7). Further 
stabilization of the boat form may be provided through the 
binding of the peptide that is linked to the MurNAc residue. 
The interaction between the acetamido group and C1 would 
also provide sufficient shielding of the oxocarbonium ion 
from solvent at the C1 atom during the reaction. It may 
even be argued that the acetamido group captures the 
oxocarbonium ion to form an oxazoline intermediate, with 






FIGURE 7: Possible structures of MurNAc intermediates in the 
SLT70-catalyzed cleavage reaction with nucleophilic participation 
by the oxygen of the 2-acetamido group. In (A) the MurNAc 
oxocarbonium ion adopts a sofa conformation, in (B) a boat 
conformation. The interactions with Glu583 and Ser487 promote 
a conformation for the 2-acetamido group in which the carbonyl 
oxygen atom may approach the Cl  atom of MurNAc. The 
interaction between the partially negatively charged oxygen atom 
of the acetamido group and the positive Cl  atom may help to 
stabilize the oxocarbonium ion intermediate and may shield the 
a-face of C1 from attack by a water molecule. 
group, which is then attacked from the “top” by the C6- 
hydroxyl group to yield the 1,6-anhydro product. To identify 
whether the proposed mechanism occurs in SLT70 will 
require further investigation. 
Structure of the SLT70-Bulgecin A Complex Biochemistry, Vol. 34, No. 39, 1995 12737 
The 3D structure of the SLT70-bulgecin A complex has 
not only increased our understanding of the catalytic mech- 
anism of SLT70 but should also permit the rational design 
of more effective lytic transglycosylase inhibitors. On a 
speculative note, such inhibitors might enhance the efficacy 
of already existing p-lactam antibiotics and, therefore, may 
even prove to be useful against penicillin-resistant bacteria. 
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